2 results
Approved WMOCompleted
The primary objective of the study is to evaluate the reduction of low density lipoprotein cholesterol (LDL-C) by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (heterozygous familial…
Approved WMOCompleted
Primary:To investigate the safety and tolerability of 60 mg 3 times daily doses of GSK2982772 in subjects with moderate to severe ulcerative colitis.Secondary:To assess the preliminary efficacy, biomarkers, histological disease activity, response…